Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYB003 in Major Depressive Disorder (EXTEND)
NCT06605105Phase 3Enrolling by invitation
- Sponsor
- Cybin Inc.
- Start
- Jul 2025
- Primary completion
- Jun 2028
- Modality
- Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of CYB003 in major depressive disorder (MDD), sponsored by Cybin Inc. Primary endpoint: Montgomery-Asberg Depression Rating Scale at Day 301. Started Jul 2025; status: enrolling by invitation.
02
Drugs
CYB003
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06605105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06605105.